NEW ORLEANS — Esperion Therapeutics’ (ESPR) experimental cholesterol drug, bempedoic acid, reduced low-density-lipoprotein cholesterol by more than 17 percent in 12 weeks and sustained those results for a full year, according to new data presented at the annual meeting of the American College of Cardiology Monday.
Those results are roughly consistent with previous studies of the drug, which is currently being reviewed by the Food and Drug Administration. But both investors and doctors will likely still have questions about side effects and safety.
About the Author Reprints
